IPCA Laboratories Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
- May 5, 2026
- Posted by: Neeraj Pandey
- Category: News
IPCA Laboratories Q4 results are expected on May 2026. Analyst consensus estimates revenue at Rs 1,850–2,050 Cr and PAT at Rs 195–235 Cr for the January to March 2026 quarter. This article covers what analysts are expecting, five key growth factors to watch, risks to the investment thesis, and a complete FAQ section for investors.
Click Here — Get Free SEBI-registered Research on IPCA Laboratories on Univest.
IPCA Laboratories Q4 FY26 Results Overview
| Company | IPCA Laboratories |
| NSE Ticker | IPCALAB |
| Sector | Pharma / Malaria / API / Domestic |
| CMP (April 2026) | Rs 1,550 |
| 52-Week High | Rs 2,200 |
| 52-Week Low | Rs 1,300 |
| Q4 FY26 Results Date | May 2026 |
| Revenue Estimate | Rs 1,850–2,050 Cr |
| PAT Estimate | Rs 195–235 Cr |
| Key Margin Metric | EBITDA 14–16% |
Data from NSE/BSE and analyst estimates. April 2026. Verify before investing.
Track live IPCA Laboratories price and analyst targets on the Univest Screener.
What to Expect from IPCA Laboratories Q4 FY26
Get Free Investment Predictions on Univest — Tap Here.
IPCA Laboratories is expected to report Q4 FY26 results on May 2026. The board meeting will consider the financial results for the quarter ended March 31, 2026. Revenue is estimated at Rs 1,850–2,050 Cr and PAT at Rs 195–235 Cr, with EBITDA 14–16% as the key operational metric. India’s Q4 FY26 earnings season runs through April and May 2026, with the Nifty 50 aggregate PAT growth expected at 8 to 12 percent YoY. Key themes across the season include margin recovery, capex normalisation, and FY27 guidance.
Budget 2026-27 Impact on Pharma
Union Budget 2026-27 continued strong support for the Pharma sector through PLI scheme continuation, infrastructure capex of Rs 11.21 lakh crore, and consumption-led demand incentives. The US 26 percent reciprocal tariff announced April 2, 2026 has created FII outflow pressure across Indian equities, but domestic policy support provides a buffer for IPCA Laboratories’s core business segments heading into Q4 FY26.
Q4 FY26 Estimates Table
| Metric | Q4 FY26 Estimate | Q4 FY25 Actual | YoY Change |
|---|---|---|---|
| Revenue | Rs 1,850–2,050 Cr | Verify on NSE | 10–15% YoY est |
| PAT | Rs 195–235 Cr | Verify on NSE | 12–18% YoY est |
| EBITDA | EBITDA 14–16% | Verify on NSE | Stable to improving |
Estimates from analyst consensus. Actual results may differ. Verify before investing.
5 Key Growth Factors to Watch in IPCA Laboratories Q4 FY26 Results
1. US Generics Revenue and Market Share
Analysts tracking IPCA Laboratories will monitor US Generics Revenue and Market Share closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.
2. Domestic Branded Formulations Volume
Analysts tracking IPCA Laboratories will monitor Domestic Branded Formulations Volume closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.
3. API Business Margin Recovery
Analysts tracking IPCA Laboratories will monitor API Business Margin Recovery closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.
4. FDA Inspection Status
Analysts tracking IPCA Laboratories will monitor FDA Inspection Status closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.
5. R&D Pipeline and ANDA Filings
Analysts tracking IPCA Laboratories will monitor R&D Pipeline and ANDA Filings closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.
Download the Univest iOS App or Android App for live Q4 FY26 results alerts and SEBI-registered analyst research on IPCA Laboratories.
5 Risk Factors for IPCA Laboratories Investors
1. FDA Warning Letter or Import Alert Risk
FDA Warning Letter or Import Alert Risk is a key monitorable for IPCA Laboratories investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.
2. US Generics Price Erosion — 5 to 8 percent Annual
US Generics Price Erosion — 5 to 8 percent Annual is a key monitorable for IPCA Laboratories investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.
3. R&D Pipeline Failure or Delay
R&D Pipeline Failure or Delay is a key monitorable for IPCA Laboratories investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.
4. Emerging Market Currency Volatility
Emerging Market Currency Volatility is a key monitorable for IPCA Laboratories investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.
5. Domestic Pricing Regulation — DPCO
Domestic Pricing Regulation — DPCO is a key monitorable for IPCA Laboratories investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.
Analyst Ratings and Targets for IPCA Laboratories
| Brokerage | Rating | 12M Target | Thesis |
|---|---|---|---|
| MOFSL | Buy | Rs 1,860 | FY27 earnings recovery; Pharma sector leadership |
| YES Securities | Buy | Rs 1,891 | Quality execution; accumulate at support |
| Kotak Institutional | Add | Rs 1,782 | Monitor Q4 FY26 result vs estimates closely |
| JM Financial | Neutral | Consensus | Await Q4 FY26 result clarity |
Analyst targets are estimates as of April 2026. These are not guaranteed returns. Verify before investing.
Subscribe to Univest Pro for SEBI-registered analyst entry, target, and stop-loss recommendations.
Q4 FY26 Earnings Calendar — Other Major Companies
| Company | Results Date |
|---|---|
| Infosys | Apr 23, 2026 |
| IndusInd Bank | Apr 24, 2026 |
| InterGlobe Aviation (IndiGo) | Apr 28, 2026 |
| IPCA Laboratories | May 2026 |
For the full Q4 FY26 results calendar, visit Univest Blogs.
Discover Pharma stocks with strong Q4 FY26 performance on the Univest Screener.
Conclusion
IPCA Laboratories (IPCALAB) Q4 FY26 results on May 2026 are a key earnings event for investors in the Pharma / Malaria / API / Domestic sector. Analyst consensus expects revenue of Rs 1,850–2,050 Cr and PAT of Rs 195–235 Cr. A beat versus estimates supports the bull case for re-rating toward analyst targets. A miss increases downside risk. Monitor results live and get instant research alerts on the Univest Screener or the Univest App. For more Q4 FY26 results previews, visit Univest Blogs.
Disclaimer: Investments in securities are subject to market risk. Please read all related documents before investing. This content is for educational purposes only and does not constitute investment advice. All analyst estimates and targets are sourced from publicly available research and may change. Verify all numbers on NSE/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.
Frequently Asked Questions
Q: When is IPCA Laboratories Q4 FY26 results date?
IPCA Laboratories Q4 FY26 results are expected on May 2026. The board meeting will consider the quarterly financials for January to March 2026. Track the announcement on NSE or the Univest Screener.
Q: What is IPCA Laboratories Q4 FY26 revenue estimate?
Analyst consensus estimates IPCA Laboratories Q4 FY26 revenue at Rs 1,850–2,050 Cr. Actual results may differ. Verify with MOFSL, YES Securities, or Kotak research once declared on May 2026.
Q: What is IPCA Laboratories Q4 FY26 PAT estimate?
Analyst consensus expects IPCA Laboratories Q4 FY26 PAT at Rs 195–235 Cr. This is an estimate based on publicly available research — actual results may vary. Track results live on the Univest Screener.
Q: Is IPCA Laboratories a buy before Q4 FY26 results?
This article does not constitute investment advice. Investors should review actual Q4 FY26 results before making investment decisions. A beat versus estimates typically supports price recovery; a miss increases downside risk. Consult a SEBI-registered financial advisor.
Q: What is IPCA Laboratories current share price?
IPCA Laboratories (NSE: IPCALAB) is trading at Rs 1,550 as of April 2026. Track the live price, FII or DII flows, and analyst ratings on the Univest Screener at univest.in/screeners.
Q: What are the key factors to watch in IPCA Laboratories Q4 FY26?
Key factors for IPCA Laboratories Q4 FY26 include: US Generics Revenue and Market Share, Domestic Branded Formulations Volume, API Business Margin Recovery. Track all these metrics on the Univest Screener.
Q: What is IPCA Laboratories FY27 outlook?
Analyst consensus expects IPCA Laboratories to deliver 12 to 18 percent earnings growth in FY27 — contingent on macro stabilisation, sector tailwinds, and execution on the growth plan outlined in Q4 FY26 management commentary.
Q: Where to track IPCA Laboratories Q4 FY26 results live?
Track IPCA Laboratories Q4 FY26 results live on the Univest Screener at univest.in/screeners. Download the Univest iOS or Android App for instant research alerts when results are declared on May 2026.
Recent Article
Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026
Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026
Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026
Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026
